Technology

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI platforms are leveling the playing field by enabling lean teams to de-risk clinical strategy, strengthen fundraising narratives, and make faster, more confident decisions across the development lifecycle.

Dave Carey, CEO, Preceptis Medical and Michael Monovoukas, CEO, co-founder, AcuityMD note the importance of shifting ear tube procedures into the office, reducing anesthesia risk, and how AI-driven data and adaptive commercial strategies are becoming critical to scaling new medtech innovations.

Poor visualization techniques can oversimplify reality and make data less potent.

Anders Romare, Advisory Board Member, causaLens, and former Novo Nordisk CDIO, outlines why artificial intelligence represents a structural turning point for the pharmaceutical industry.

The AI dilemma facing biopharma—and what’s at risk.

Pharmaceutical manufacturers must address the question of how exactly does value get created and destroyed inside these organizations and how will AI fundamentally shift that equation?

AI’s transformative potential in clinical development relies on the industry's ability to rebuild its fractured data infrastructure.

Outlining the big questions and considerations for pharma companies in determining their readiness for this transformation—and achieving true “AI Advanced” status.

The filing follows the completion of a pivotal study targeting abdominal conditions.

New technologies are helping the industry move toward more predictive and humane approaches.

Start managing the transformation now to secure every benefit.

From CRM saturation to commercial orchestration.

Eli Lilly and NVIDIA unveil a groundbreaking AI supercomputer, revolutionizing drug discovery and accelerating patient care through advanced technology.

AI transforms pharmaceutical operations by automating workflows, ensuring transparency, and enhancing compliance, driving efficiency and innovation in healthcare.

A blueprint for how companies can move from isolated pilots toward effective AI implementation.

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

Nabla Bio and Takeda enhance their partnership to revolutionize AI-driven protein therapeutics, aiming for groundbreaking advancements in drug development.

Developing a medical AI model is defining the parameters of the problem that needs to be solved.

Avak Kahvejian, PhD, a general partner with biotech incubator Flagship Pioneering, discusses how AI is rearchitecting methods—and mindsets—in drug discovery and development.

Merck’s executive director, operations lead, global medical affairs and outcomes research discusses how data is helping to identify scientific leaders.

The key steps for pharma in pivoting from proof-of-concept experimenting to enterprise-scale value.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately identify and understand both key and digital opinion leaders is vital for effective engagement.

A Harvard Business School Healthcare Alumni Q&A with Professor Eric Mazur of Harvard University.

Powering learnings of the dark genome to tackle disease at its source.